Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-06-06 | New | $10,473,043 | $10,473,043 | Equity Only | 06b | SEC link |
| 2024-05-01 | New | $6,987,025 | $6,987,025 | Other | 06b | SEC link |
| 2019-10-23 | Amended | $13,728,492 | $10,728,492 | Equity Only | 06b | SEC link |
| 2018-09-27 | New | $3,000,000 | $3,000,000 | Equity Only | 06b | SEC link |
| 2017-09-07 | New | $411,387 | $411,387 | Debt Only | 06b | SEC link |
| Name | Role |
|---|---|
| James Bartlett | Director |
| Jennifer J. Davagian | Director, Executive |
| John S. Davagian | Director |
| John S. Davagian Ii | Director |
| Mark C. Ensign | Executive |
| Henry Kay | Director |
| Marc Keller | Director |
| Ernest H. Pomerantz | Director |
| David Shepard | Director |
| David Shepherd | Director |
| Richard Warburg | Director |